3038r_ind_1023-1041 4/11/01 2:14 PM Page 1023

INDEX

A Allergic phytodermatitis (APD), 26–28, , 600, 601f, 602 28f–29f apocrine sweat gland, 14–16, 15f, 17f Allopurinol, drug reaction to, 554 tuberculosis, metastatic, 661–662, 664, 666 ALM (acral lentiginous melanoma), 295–296, Acantholytic dermatosis, transient, 112, 113f 297f Acanthosis nigricans (AN), 82–83, 83f Alopecia classification, 82 nonscarring, 928–940 malignant, 82–83, 493, 493f–494f , 928–930, 929f, 931f ACD. See Allergic contact dermatitis , 928 ACDRs (adverse cutaneous drug reactions). , 928, 931f See Drug reactions , 940, 940f ACE (angiotensin-converting enzyme) inhib- androgenetic alopecia, 932–936, 933f, itors, reactions to, 556 935f–936f Acetowhitening, 1015 neoplastica, 482 keloidalis, 941, 945f , 937–939, 938t–939t, Acne . See Rosacea 939f Acne vulgaris, 2–6, 3f, 5f, 7f scarring, 941, 942f–945f, 942t , 4 α1 antitrypsin-deficiency panniculitis, 146 , 4 Amiodarone-induced pigmentation, 566, 567f recalcitrant acne, 4 Amoxicillin drug reaction, 554 Acneform drug eruptions, 548 Ampicillin drug reaction, 553f, 554 Acral lentiginous melanoma (ALM), 295–296, Amyloidosis, systemic, 334–336, 335f, 337f 297f acquired, 334–336, 335f, 337f Acrochordon, 209f secondary, 334, 336 Acrodermatitis continua of Hallopeau, 69 AN. See Acanthosis nigricans Acrodermatitis enteropathica, 430–431, 432f Anagen effluvium, 940, 940f Acrosclerosis, 375f Anaphylaxis and anaphylactoid reactions, 547, ACTH-induced pigmentation, 568 556, 558 Actinic keratosis, 217, 219, 220f Angioedema and urticaria, 338–344, 339f, Actinic prurigo, 230, 234 341f–343f, 344t, 345f Acute febrile neutrophilic dermatosis. See drug reaction, 547, 556–558, 559f Sweet’s syndrome urticaria perstans, 393–394, 394f Acute retroviral syndrome (ARS), 912–915, urticarial vasculitis, 393–394, 394f 915f, 915t Angiokeratoma, 183f AD. See Atopic dermatitis Angioma Addison’s disease, 424, 424f cherry, 181f Adult T cell leukemia/lymphoma (ATLL), spider, 182f 532–533, 533f–534f Angiomatous nevus (capillary hemangioma of Adverse cutaneous drug reactions (ACDRs). infancy), 173–174, 174f–175f See Drug reactions Angioneurotic edema, 556–558, 559f Albinism, 322–324, 325f–326f Angiotensin-converting enzyme (ACE) in- classification, 322, 323t hibitors, reactions to, 556 iris translucency with, 326f Anogenital warts. See Human papillomavirus, ocular, 322, 323t, 324 sexually transmitted oculocutaneous, 322, 323t, 324, 325f–326f Antibiotics, reaction to, 556 Aleppo sore. See Leishmaniasis Antimalarial-induced pigmentation, 567 Allergic contact dermatitis (ACD), 26–28, 28f–29f Anus. See Genitalia, perineum, and anus, dis- anogenital, 995, 995f orders of Allergic cutaneous vasculitis, 381–384, APD (allergic phytodermatitis), 26–28, 382f–383f 28f–29f

INDEX 1023 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1024

Aphthous ulcer, 976–977, 977f , 586–603 Apocrine sweat gland abscess, 14–16, 15f, 17f abscess, furuncle, and , Apocrinitis, 14–16, 15f, 17f 600–602, 601f, 603f ARS (acute retroviral syndrome), 912–915, and , 586–590, 915f, 915t 587f–589f, 591f Arterial insufficiency, 452–457 infectious . See Infectious folli- Arterial spider, 182f culitis Arthralgia-myalgia syndrome, 377 pathogenesis, 586 Arthropod bites, 820–825, 822f–825f sepsis and septic shock, 636–640, 639f, Asteatotic dermatitis, 49, 49f 641f Atheroembolization, 452–457, 455f–456f epidemiology, 636 Atherosclerosis, 452–457, 453f–454f management, 640 Atherosclerosis obliterans (ASO), 453f–455f physical examination, 637–638 Athlete’s foot, 688–690, 689f, 691f–692f soft tissue infections (STIs), 604–619 ATLL (adult T cell leukemia/lymphoma), . See Cellulitis 532–533, 533f–534f , 604 Atopic dermatitis (AD), 30–35, 31f–33f, 35f . See Erysipelas anogenital, 996 etiology, 605t–606t epidemiology, 30 , 604, 618, 619f lichenification, 31, 31f, 35f necrotizing soft tissue infection (NSTI), management, 34–35 604 Atopic eczema, 30–35, 31f–33f, 35f superficial cutaneous infections, 580–585 Atrophoderma of Pasini and Pierini, 126f , 580–582, 581f Auspitz’s sign, 1016 intertrigo, 584, 584f–585f Autoimmune diseases, skin signs of. See Im- , 582–583, 583f mune, autoimmune, and rheumatic dis- therapy (antimicrobial agents), 682t–683t eases, skin signs of Baghdad (button). See Leishmaniasis Autosensitization dermatitis, 44, 44f Bairnsdale ulcer, 668–669, 669f Balanoposthitis, 718, 719f B Baldness. See Alopecia , 646–648, 647f Barbiturates, drug reactions to, 554 Bacterial infections involving the skin, Bartonella infections, 642–648 580–683 bacillary angiomatosis, 646–648, 647f gram-negative infections, 642–653 cat-scratch disease/fever, 643–644, 645f bacillary angiomatosis, 646–648, 647f overview, 642, 642t Bartonella infection overview, 642, 642t Basal cell carcinoma (BCC), 261–265, cat-scratch disease/fever, 643–644, 645f 261f–265f Pseudomonas aeruginosa infections, Basal cell nevus syndrome, 266–268, 652–653 267f–268f , 649–650, 651f Bazin’s disease, 395, 396f gram-positive infections associated with BCC (basal cell carcinoma), 261–265, toxin production, 620–629 261f–265f , 626–628, 627f, 629f Beau’s lines, 968, 972f staphylococcal scalded-skin syndrome Becker’s nevus, 198f (SSSS), 620–622, 621f, 623f Bed sore, 474–477, 475f–476f , 624–626, 625f Bedbugs, 821, 823f infective endocarditis. See Infective endo- Behçet’s syndrome/disease, 346–348, carditis 347f–348f Lyme borreliosis. See Lyme borreliosis Benign neoplasms and hyperplasias, 160–209 mycobacterial infections, 654–671 Becker’s nevus, 198f cutaneous nontuberculous infections, dermatofibroma, 204, 205f 666–671 digital myxoid , 191f cutaneous tuberculosis, 661–666, disorders of blood vessels. See Blood vessel 663f–665f disorders epidemiology, 654 disorders of melanocytes. See Melanocytes, . See Leprosy disorders of

1024 INDEX 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1025

epidermal inclusion cyst, 190f diabetic, 412, 412f epidermal nevus, 202f Bullous diseases, 84–105 , 188f with oral manifestations, 980–982, hypertrophic scars and keloids, 206–207, 980f–982f 207f–208f Bullous drug eruptions, 548 keratoacanthoma (KA), 196, 197f , 588, 589f lipoma, 203f Bullous pemphigoid, 98–100, 99f–100f , 190f , 668–669, 669f nevus sebaceous, 201f Busulfan-induced pigmentation, 568 , 200f seborrheic keratosis, 192–193, 193f–195f C skin tag, 209f Calcification, widespread systemic, 417–418, syringoma, 199f 418f , 189f Calciphylaxis, 417–418, 418f trichoepithelioma, 199f Calcium channel blockers, reaction to, 556 Benzodiazepines, drug reactions to, 554 Campbell de Morgan spots, 181f Berloque dermatitis, 221, 222f Cancers Birthmarks, classification of, 173 epidermal. See Epidermal precancers and Bites, insect. See Insect bites and infestations cancers Black dot tinea capitis variant, 700–702, nonmelanoma, variation in HIV disease, 702f–703f 924 Black flies, 821 systemic, skin signs of, 478–495 Blennorrhagia, 885–886, 886f acanthosis nigricans, malignant, 82–83, Blennorrhea, 885–886, 886f 493, 493f–494f Bleomycin-induced pigmentation, 568 Cowden’s syndrome (multiple hamar- , 8 toma syndrome), 488, 489f Blister beetles, 821 glucagonoma syndrome, 490, 491f Blood vessel disorders, 173–187 metastatic cancer to the skin, 479–483, angiokeratoma, 183f 480f–481f, 483f capillary hemangioma of infancy (CHI), patterns of cutaneous involvement, 173–174, 174f–175f 479–480, 482 capillary/venous/lymphatic (CVL) malfor- Paget’s disease, 484–487, 485f, 487f mations, 179, 180f paraneoplastic pemphigus (PNP), 495, cherry angioma, 181f 495f glomus tumor, 186f Peutz-Jeghers syndrome (PJS), 492, 492f lymphatic malformation (lymphangioma), Candida leukoplakia, 714–716, 715f, 717f 187f Candidiasis, 708–721 port-wine stain, 176, 177f–178f chronic mucocutaneous, 720, 721f pyogenic granuloma, 184, 185f classification, 709 spider angioma, 182f cutaneous, 710–713, 710f–713f vascular birthmark classification, 173 epidemiology, 708 venous lake, 180f genital, 718–720, 719f Blue neuronevus, 166, 167f management, 709 Blue nevus, 166, 167f mucosal, variation in HIV disease, 924 Blue rubber bleb nevus, 179 oropharyngeal, 714–716, 715f, 717f Botfly, 822, 824f Candidosis. See Candidiasis Bouton d’Orient. See Leishmaniasis Canker sore, 976–977, 977f Bowenoid papulosis, 869 Capillary hemangioma of infancy (CHI), Bowen’s disease, 255, 256f 173–174, 174f–175f Brazilian pemphigus, 96 Capillary/venous/lymphatic (CVL) malforma- Breast cancer, 480, 481f tions, 179, 180f Brocq, pseudopelade of, 941, 942f–943f Carbamazepine drug reaction, 554 Brunsting-Perry pemphigoid, 101 Carbuncle, 600, 602, 603f Buccal and gingival mucosa, disorders of, Carcinoma telangiectaticum, 479 976–979, 977f–978f Carotene-induced pigmentation, 568 Bullae, 1011–1012 Cat-scratch disease/fever, 643–644, 645f

INDEX 1025 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1026

Caterpillars, 821 Contact dermatitis, 18–23, 19f, 21f, 22t, 23f, Cave disease, 737–738, 739f 23t Cavernous hemangioma, 173, 179, 180f allergic contact dermatitis, 18–20, 21f, 22, CDLE (classic chronic discoid lupus erythe- 22t–23t, 23f, 26–28, 28f–29f matosus), 369–370, 371f common contact allergens, 23t Cellulitis, 604, 606–613, 609f, 611f, 613f irritant contact dermatitis (ICD), 18–20, epidemiology, 606–607 19f, 22, 22t, 24–25 gangrenous, 604, 614–617 etiologic agents, 24 clostridial soft tissue infections, 616 toxic contact dermatitis of the hands, 20, immunocompromised individuals, 617 21f (NF), 614, 616 Cowden’s syndrome, 488, 489f nonclostridial anaerobic, 616 Crab lice (pediculosis pubis), 830–832, progressive bacterial synergistic gan- 831f–832f grene, 616 Cradle cap, 45–48, 46f infecting organisms, 607, 610 Cranial arteritis, 390–391, 391f–392f Cercarial dermatitis, 848t, 849, 849f Creeping eruption. See Cutaneous larva mi- , 901–904 grans Chemotherapeutic agents, reaction to, 556 Creeping verminous dermatitis. See Cutaneous Cherry angioma, 181f larva migrans CHI (capillary hematoma of infancy), Crest syndrome, 374, 377, 377f 173–174, 174f–175f Crusts, 1013f Chicago disease, 740–742, 741f Cryoglobulinemia, 504–506, 505f, 507f Chickenpox (varicella), 801–804, 803f classification, 504 Chigoe, 821 Cryptococcosis, 734–736, 735f Chloasma, 327–328, 329f CTCL. See Cutaneous T cell lymphoma Chloroquine-induced pigmentation, 567 Cushing’s syndrome, 420, 420f Chlorpromazine-induced pigmentation, 568 Cutaneous B cell lymphoma, 543, 543f–544f Chromoblastomycosis, 729–730, 730f Cutaneous horn, 250, 251f Chromomycosis, 729–730, 730f Cutaneous larva migrans (CLM), 844–846, Chronic venous insufficiency (CVI), 462–467, 845f, 845t, 847f 463f, 465f–466f Cutaneous lymphomas and sarcoma. See Cicatricial pemphigoid, 101, 101f Lymphomas and sarcoma Cicatrizing perifolliculitis, 14 Cutaneous melanoma. See Melanoma Clam digger’s itch, 848t, 849, 849f Cutaneous necrosis drug reaction, 548–549, Clap, 885–886, 886f 549f Clark melanocytic nevus (CMN), 272–276, Cutaneous papilloma, 209f 274t, 275f, 277f Cutaneous T cell lymphoma (CTCL), Classic chronic discoid lupus erythematosus 535–537, 537f–541f (CDLE), 369–370, 371f classification, 536t–537t CLM (cutaneous larva migrans), 844–846, management, 536–537 845f, 845t, 847f Sézary’s syndrome, 535, 537, 542 Clofazimine-induced pigmentation, 566 CVI (chronic venous insufficiency), 462–467, Clostridial soft tissue infections, 616 463f, 465t–466f CMN (Clark melanocytic nevus), 272–276, CVL (capillary/venous/lymphatic) malforma- 274t, 275f, 277f tions, 179, 180f CNN (congenital nevomelanocytic nevus), Cyclophosphamide-induced pigmentation, 278–280, 279f, 281f 568 Cold sore. See Herpes simplex virus Cystic acne, 4 Collodion baby, 76, 80, 81f , 188–191 Common acne (acne vulgaris), 2–6, 3f, 5f, 7f digital myxoid, 191f Condyloma acuminatum, 986, 986f–987f. See epidermal, 188f also Human papillomavirus, sexually epidermal inclusion, 190f transmitted epidermoid, 188f Congenital nevomelanocytic nevus (CNN), isthmus catagen, 189f 278–280, 279f, 281f milium, 190f Consumption, 661 mucous, 191f

1026 INDEX 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1027

pilar, 189f management of, 686–687 sebaceous, 188f variation in HIV disease, 924 trichilemmal, 189f Dermatosis Cytostatic agents, drug reaction to, 556 digitate, 109, 110f Cytoxan-induced pigmentation, 568 ichthyosiform, 70–83 linear IgA, 105, 105f D papulosa nigra, 194f Darier’s sign, 514, 515f, 1016 pigmented purpuric, 131–133, 132f–133f Darling’s disease, 737–738, 739f Dermopathy, diabetic, 414, 414f Decubitus ulcer, 474–477, 475f–476f Desert fever, 743–745 Deep congenital nevomelanocytic nevus, 278 Desmoplastic melanoma, 293–294, 294f Deep venous thrombosis, 458, 460, 461f Desquamation (scaling), 1013f predisposing factors, 458t Diabetes mellitus (DM), 411–418 Deerfly fever, 649–650, 651f associated skin diseases, 411t Delhi boil (button). See Leishmaniasis calciphylaxis, 417–418, 418f Demodicidosis, 595 classification, 411 Dercum’s disease, 203f diabetic bullae, 412, 412f Dermal melanocytoma, 166, 167f diabetic dermopathy, 414, 414f Dermatitis diabetic foot, 413, 413f asteatotic, 49, 49f diabetic neuropathy, 413, 413f atopic, 30–35, 31f–33f, 35f necrobiosis lipoidica, 415–416, 416f autosensitization, 44, 44f Diagnosis, clinical and laboratory aids to, Berloque, 221, 222f 1015–1017 cercarial, 848t, 849, 849f biopsy, 1017 contact. See Contact dermatitis clinical examination techniques, 1015 eczematous, 18–49 clinical signs and tests, 1016 hands, toxic contact dermatitis of, 20, 21f microscopic examination, 1016–1017 lime, 221, 222f Diaper dermatitis, 710, 713f perioral, 12, 13f Diascopy, 1015 periorbital, 13f Digital myxoid cyst, 191f radiation. See Radiation dermatitis Digitate dermatosis, 109, 110f seborrheic, 45–48, 46f–47f Discoid eczema, 42, 43f stasis, 462, 464, 465f, 469 Disseminated coccidioidomycosis, 743–744, Dermatitis herpetiformis (DH), 102–103, 104f 745f Dermatofibroma, 204, 205f Disseminated cryptococcosis, 734–736, 735f Dermatofibrosarcoma protuberans, 545, 545f Disseminated intravascular coagulation (DIC), Dermatoheliosis, 214–219, 215f, 218f, 220f 500–502, 501f, 503f solar keratosis, 217, 219, 220f DM. See Diabetes mellitus solar lentigo, 217, 218f Donovanosis, 905–906, 906f Dermatomes, 810f–811f Drug rash with eosinophilia and systemic Dermatomyositis, 349–351, 350f–352f symptoms (DRESS), 564–565, 565f drug reaction, 548 Drug reactions, 546–571 Dermatophytic folliculitis, 594, 597f acneform eruptions, 548 Dermatophytoses, 684–707 anaphylaxis and anaphylactoid, 547, 556, classification, 685 558 epidemiology, 684–685 angioedema, 547, 556–557 of epidermis, 688–699 bullous eruptions, 548 tinea corporis, 696–697, 696f–697f cutaneous necrosis, 548–549, 549f tinea cruris, 694, 695f dermatomyositis-like reactions, 548 tinea facialis, 698–699, 698f–699f, 707f drug hypersensitivity syndrome, 564–565, tinea incognito, 699, 699f 565f tinea manuum, 693–694, 693f eczematous eruptions, 548 tinea pedis, 688–690, 689f, 691f–692f edema, 556 of hair, 700–707 erythema multiforme, 547 tinea barbae, 706, 706f–707f erythema nodosum, 548 tinea capitis, 700–704, 701f–702f, 705f erythroderma, 548

INDEX 1027 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1028

exanthematous, 547, 552–555, 553f Endocrine diseases. See Genetic, metabolic, specific drugs, 554 endocrine, and nutritional diseases exfoliative dermatitis, 153t, 156f, 548 Endothrix tinea capitis, 700–701 fixed drug eruptions, 547, 560–562, 561f, Eosinophilic folliculitis (EF), 916–918, 917f 563f EPD (extramammary Paget’s disease), specific drugs, 560 486–487, 487f , 950, 951f Epidermal cyst, 188f immunologically mediated, 550t Epidermal inclusion cyst, 190f injecting drug use, cutaneous signs of, 570, Epidermal nevus, 202f 571f syndrome, 202f , 116t Epidermal precancers and cancers, 248–251 lichenoid eruptions, 547 cutaneous horn, 250, 251f life-threatening, 546–547 epithelial precancerous lesions, 248–249 lupus erythematosus-like syndrome, 548 solar keratosis, 217, 219, 220f management, 550 Epidermodysplasia verruciformis, 762 overview, 546–549 Epidermoid cyst, 188f pemphigus vulgaris, 96 Epidermolysis bullosa (EB), 84–90, 85f, 86t, photosensitivity, 223–229, 547 87f, 88t, 89f, 91f pigmentation reactions, 549, 566–568, 567f, dystrophic, 86t, 88, 89f, 91f 569f generalized atrophic benign epidermolysis specific drugs, 566–568 bullosa (GABEB), 86, 86t, 87f pityriasis rosea-like reactions, 548 junctional, 86, 86t, 87f porphyria cutanea tarda, 547 simplex, 84, 86t pseudolymphoma, 548 Epidermolytic hyperkeratosis, 78, 79f psoriasiform reactions, 548 Epithelial precancerous lesions, 248–249 purpura, 547–548 Epithelioid spindel cell-nevus, 168–169, 169f pustular eruptions, 548 Erysipelas, 604, 606–613, 608f scleroderma-like reactions, 377, 548 epidemiology, 606–607 serum sickness, 547 infecting organisms, 607, 610 Stevens-Johnson syndrome (SJS), 547 , 611f toxic epidermal necrolysis (TEN), 547 , 395, 396f urticaria, 547, 556–558, 559f Erythema infectiosum, 778–780, 779f–780f variation in HIV disease, 924 Erythema multiforme Drug use, cutaneous signs of, 570, 571f drug reaction, 547 Duckhunter’s itch. See Cutaneous larva migrans Erythema multiforme syndrome, 136–138, Dyshidrotic eczematous dermatitis, 39–40, 41f 137f–139f Dysmorphic syndrome, 579 distribution, 138f Dysplastic melanocytic nevus, 272–276, 274t, major, 136 275f, 277f maximal variant, 136 minor, 136 E Erythema nodosum EB. See Epidermolysis bullosa drug reaction, 548 Ecthyma, 586–591, 591f Erythema nodosum syndrome, 144, 145t Ecthyma gangrenosum, 604 etiology, 145t Eczema Erythema nuchae, 176 atopic dermatitis, 30–35, 31f–33f, 35f Erythrasma, 580–582, 581f craquelé, 49, 49f Erythroderma dermatitis, 18–49 in acutely ill patients, 152–154, 153t, discoid, 42, 43f 155f–157f drug reaction, 548 drugs associated with, 153t nummular, 42, 43f etiology, 153t Edema drug reaction, 556 drug reaction, 153t, 548 EF (eosinophilic folliculitis), 916–918, 917f Erythrohepatic protoporphyria, 245–247, Elephantiasis nostras verrucosa, 469 246f–247f En cuirasse metastatic carcinoma, 479–480 Erythroplasia, 983, 983f

1028 INDEX 3038r_ind_1023-1041 4/17/01 3:03 PM Page 1029

of Queyrat, 260f necrotizing fasciitis (NF), 614, 616 Erythropoietic porphyria, 245–247, 246f–247f nonclostridial anaerobic, 616 Espundia. See Leishmaniasis progressive bacterial synergistic , Esthiomene, 908 616 Estrogen-induced pigmentation, 568 , 615t, 616 European blastomycosis, 734–736, 735f GCNN (giant congenital nevocellular nevus), Exanthematous drug reactions, 547, 552–555, 276, 278, 280, 281f 553f GD (Grover’s disease), 112, 113f specific drugs, 554 Genetic, metabolic, endocrine, and nutritional Exanthems, infectious, 766–780 diseases, 406–451 Exfoliative dermatitis drug reaction, 548 Addison’s disease, 424, 424f Exfoliative erythroderma syndrome, 152–154, Cushing’s syndrome and hypercorticism, 153t, 155f–157f 420, 420f External genital warts. See Human papillo- diabetes. See Diabetes mellitus mavirus, sexually transmitted generalized pruritus without diagnostic skin Extramammary Paget’s disease (EPD), lesions, 425–427 486–487, 487f Graves’ disease and hyperthyroidism, 421, 421f F hereditary hemorrhagic telangiectasia, 419, Fabry’s disease, 183f 419f Factitious syndromes, 578, 578f hypothyroidism and myxedema, 422–423 Familial benign pemphigus, 92, 93f neurofibromatosis (NF), 440–442, 441f, 443f Familial lipoma syndrome, 203f pellagra, 433, 433f Farmer’s skin, 214 pregnancy, diseases in, 406–410 Fever blister. See Herpes simplex virus pseudoxanthoma elasticum (PXE), Fibroma, oral, 979 434–436, 435f–436f Fibrous nodule, 979 scurvy, 428–429, 429f Fifth disease (erythema infectiosum), tuberous sclerosis, 437–438, 438f–439f 778–780, 779f–780f xanthelasma, 445, 446f Fish tank granuloma, 666–668, 667f xanthomas. See Xanthomas Fissured tongue, 975, 975f zinc deficiency and acrodermatitis entero- Fixed drug eruptions, 547, 560–562, 561f, pathica, 430–431, 431f–432f 563f Genital herpes, 874–881, 876f–879f specific drugs, 560 epidemiology, 874 Fleas, 821–822, 822f management, 880–881 Flies, 821–822 pathogenesis, 875 Focal fibrous hyperplasia, 979 physical examination, 875 Follicular eczema, 31, 32f primary, 875, 876f Follicular occlusion syndrome, 14 progenitalis. See Herpes simplex virus Folliculitis, syphilitic, 595 recurrent, 875, 877f–879f , 941, 944f Genital warts. See Human papillomavirus, Fordyce, angiokeratoma of, 183f sexually transmitted Fournier’s gangrene, 616 Genitalia, perineum, and anus, disorders of, Fungal infections 988–1007 HIV disease, 925 allergic contact dermatitis (ACD), 995, 995f skin and hair. See Skin and hair, fungal in- atopic dermatitis, 996 fections of genital lentiginoses, 988, 989f Furuncle, 600, 601f, 602, 603f lichen planus (LP), 993, 993f–994f lichen sclerosus (LS), 998, 999f G lichen simplex chronicus, 996, 996f GA (granuloma annulare), 120–122, 121f precancerous and cancerous lesions, variants, 120 1000–1007 Gangrenous cellulitis, 604, 614–617 HPV-induced squamous intraepithelial le- clostridial soft tissue infections, 616 sion and squamous cell carcinoma in immunocompromised individuals, 617 situ, 1002, 1003f

INDEX 1029 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1030

invasive anogenital squamous cell carci- GVHD. See Graft-versus-host disease noma, 1004, 1004f–1005f malignant melanoma of the anogenital H region, 1006, 1006f–1007f Hailey-Hailey’s disease, 92, 93f squamous cell carcinoma in situ (SCC), Hair 1000, 1000f–1001f dermatophytoses, 700–707 pruritus ani, 996, 997f follicle disorders and related disorders, psoriasis vulgaris, 991, 991f–992f 926–951 vitiligo and leukoderma, 990, 990f growth disorders. See Alopecia Geographic tongue, 975, 975f , 946–948, 947f, 949f Geographical breakdown of infectious disease hypertrichosis, 950, 951f incidence, 1018–1021 drug-induced, 950, 951f German measles, 770–771, 771f–772f hypertrichosis lanuginosa, 950 Giant cell arteritis, 390–391, 391f–392f fungal infections. See Skin and hair, fungal Giant congenital nevocellular nevus (GCNN), infections of 276, 278, 280, 281f Hairy tongue, 974, 974f Gilchrist’s disease, 740–742, 741f Hallopeau, acrodermatitis continua of, 69 Gingival and buccal mucosa, disorders of, Halo nevomelanocytic nevus, 164, 165f 976–979, 977f–978f Hand-foot-and-mouth disease (HFMD), Glomus tumor, 186f 776–778, 777f Glossitis migrans, 975, 975f Hand-Schüller-Christian disease, 508–512, Glucagonoma syndrome, 490, 491f 509f, 509t–510t, 511f, 513f Gnathophyma, 8 Hands, toxic contact dermatitis of, 20, 21f Gold-induced drug reactions, 554, 568 Hansen’s disease. See Leprosy Gonococcal arthritis-dermatitis syndrome, Harlequin fetus, 80 887, 888f Heerford syndrome, 403 , 887, 888f Helminths, 845t , 885–886, 886f Hemangiomas of infancy, 173–174, 174f–175f Gougerot-Blum disease, 131, 133 Hematologic diseases, skin signs of, 496–521 Graft-versus-host disease (GVHD), 353–357 cryoglobulinemia, 504–506, 505f, 507f acute, 353–354, 353t, 354f–355f disseminated intravascular coagulation chronic, 355–356, 356f–357f (DIC), 500–502, 501f, 503f Graham Little syndrome, 114 Langerhans cell histiocytosis (LCH), Gram-negative bacterial infections, 642–653 508–512, 509f, 509t–510t, 511f, 513f Bartonella infections, 642–648 leukemia cutis (LC), 518–520, 519f, 521f folliculitis, 594 mastocytosis, 514–516, 514t, 515f, 516t, 517f Pseudomonas aeruginosa infections, thrombocytopenic purpura, 496–498, 497f, 652–653 499f tularemia, 649–650 Hemiptera, 822 Gram-positive bacterial infections associated Heparin-induced necrosis, 549, 551f with toxin production, 620–629 Hereditary epidermolysis bullosa. See Epider- scarlet fever, 626–628, 627f, 629f molysis bullosa staphylococcal scalded-skin syndrome Hereditary (hair) thinning, 932–936, 933f, (SSSS), 620–622, 621f, 623f 935f–936f toxic shock syndrome, 624–626, 625f Herpes febrilis. See Herpes simplex virus Granuloma annulare (GA), 120–122, 121f Herpes gestationis, 409–410, 410f variants, 120 Herpes gladiatorum. See Herpes simplex , 905–906, 906f virus Granuloma telangiectaticum, 184 Herpes labialis. See Herpes simplex virus Granuloma venereum, 905–906, 906f Herpes simplex virus (HSV), 781–785, 785f Graves’ disease, 421, 421f epidemiology, 781, 783 Great imitator. See genital infections. See Genital herpes Grover’s disease (GD), 112, 113f infections associated with systemic im- Guttate parapsoriasis, 134, 135f munocompromise, 794–798, 795f, of Juliusberg (pityriasis lichenoides chron- 797f, 799f, 925 ica), 134 management, 784–785

1030 INDEX 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1031

neonatal, 789–790, 790f–791f Human papillomavirus (HPV) infections, nongenital infection, 786–787, 787f 760–765 widespread cutaneous infection associated epidemiology, 760–761 with cutaneous immunocompromise, epidermodysplasia verruciformis, 762 791–793, 792f–793f management, 764 Herpes zoster (HZ), 805–808, 807f, 809f sexually transmitted, 862–873, 863f–867f Herpetic folliculitis, 595–596, 599f management, 866–868 Herpetic . See Herpes simplex virus squamous cell carcinoma of anogenital HFMD (hand-foot-and-mouth disease), skin, 869–872, 870f–873f 776–778, 777f types and associated lesions, 761t HHV. See Human herpesviruses variation in HIV disease, 925 axillaris, 14–16, 15f verruca plana (flat warts), 761–762, 765f , 14–16, 15f, 17f verruca plantaris (plantar warts), 761–762, management, 16 765f Hirsutism, 946–948, 947f, 949f verruca vulgaris (common warts), 761–762, Histamine-releasing drugs, reaction to, 556 762f–763f Histiocytosis, type II, 508–512, 509f, Hydantoin derivatives drug reaction, 554 509t–510t, 511f, 513f Hydroxychloroquine-induced pigmentation, Histoplasmosis, 737–738, 739f 567 HIV disease, 910–925 Hymenoptera, 821, 823 acute HIV syndrome, 912–915, 915f, 915t Hypercorticism, 420, 420f eosinophilic folliculitis (EF), 916–918, Hyperkeratosis, epidermolytic, 78, 79f 917f Hyperpigmentation following inflammatory Kaposi’s sarcoma, 525–526, 528, 530f–531f disorders, 330, 330f lipodystrophy syndrome, 921–923, Hyperplasias. See Benign neoplasms and hy- 922f–923f perplasias oral hairy leukoplakia (OHL), 919–920, Hypersensitivity syndrome, drug-induced, 920f 564–565, 565f overview, 911t Hypersensitivity vasculitis, 381–384, tuberculosis, 661 382f–383f variations of common mucocutaneous dis- Hyperthyroidism, 421, 421f orders in HIV disease, 924–925 Hypertrichosis, 950, 951f aphthous stomatitis, 924 Hypertrophic scars, 206–207, 207f dermatophytoses, 924 Hypomelanosis, postinflammatory, 332f drug eruptions, 924 Hypopigmentation following inflammatory herpes simplex virus infection, 794, 925 disorders, 331, 331f–333f human papilloma virus (HPV), 925 Hypothyroidism, 422, 423f invasive fungal infection with cutaneous HZ (herpes zoster), 805–808, 807f, 809f dissemination, 925 molluscum contagiosum, 925 I mucosal candidiasis, 924 ICD (irritant contact dermatitis), 18–20, 19f, nonmelanoma skin cancers, 924 22, 22t, 24–25 syphilis, 900, 925 Ichthyoses, 70–81 varicella zoster virus infection, 925 epidermolytic hyperkeratosis, 78, 79f , 594, 595f ichthyosis vulgaris, 70–72, 71f–73f Houseflies, 822, 825f distribution, 72f Human herpesviruses (HHV), 781–799 lamellar ichthyosis, 76–77, 77f herpes simplex virus (HSV). See Herpes newborn (collodion baby), 80, 81f simplex virus X-linked ichthyosis (XLI), 74–75, 75f human herpesvirus-6 and -7 infections (ex- Ichthyosiform dermatoses, 70–83 anthema subitum), 818, 819f IgE dermatitis, 30–35, 31f–33f, 35f immunocompromised individuals, 782t ILVEN (inflammatory linear verrucous epider- overview, 781, 782t mal nevus), 202f varicella-zoster virus (VSV) infections. See Immune, autoimmune, and rheumatic dis- Varicella-zoster virus infections eases, skin signs of, 334–405 Human orf, 758, 759f Immunotherapeutics, drug reaction to, 556

INDEX 1031 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1032

Impetigo, 586–590, 587f–589f Invasive fungal infections, 726–745 Infections chromomycosis, 729–730, 730f bacterial. See Bacterial infections involving disseminated coccidioidomycosis, 743–744, the skin 745f fungal disseminated cryptococcosis, 734–736, 735f HIV disease, 925 histoplasmosis, 737–738, 739f skin and hair. See Skin and hair, fungal in HIV disease, 925 infections of mycetoma, 726–728, 727f, 728t by geographic area, 1018–1021 North American blastomycosis, 740–742, viral. See Viral infections of skin and mu- 741f cosa sporotrichosis, 731–732, 733f Infectious folliculitis, 592–599 Invasive squamous cell carcinoma (SCC), Candida albicans, 594 257–260, 984, 984f classification, 593 Iron-induced pigmentation, 568 demodicidosis, 595 Irritant contact dermatitis (ICD), 18–20, 19f, dermatophytic, 594, 597f 22, 22t, 24–25 gram-negative, 594 Irritation fibroma, 979 herpetic, 595–596, 599f Isoniazid drug reaction, 554 hot tub, 594, 595f Isthmus catagen cyst, 189f management, 596, 598t molluscum syncosis, 595 J Pityrosporum, 594, 599f Janeway lesions, 631f, 632 S. aureus, 592, 593f–594f, 594 Jock itch, 694, 695f syphilitic, 595 tinea capitis, 594 K Infective endocarditis, 630–634, 635f Kala-azar. See Leishmaniasis cutaneous manifestations, 633t Kaposi’s sarcoma (KS), 525–529, 527f, epidemiology, 630 529f–531f Janeway lesions, 631f, 632 African-endemic, 525, 528 Osler’s nodes, 632, 633f classic, 525, 527f, 528 Infestations. See Insect bites and infestations HIV-associated, 525–526, 528, 530f–531f Inflammatory disorders, 106–151 iatrogenic immunosuppression-associated, hyperpigmentation following, 330, 330f 525–526, 528 hypopigmentation following, 331, management, 528–529 331f–333f Kasabach-Merritt syndrome, 174 inflammatory linear verrucous epidermal Kawasaki’s disease (KD), 397–399, 398f–399f nevus (ILVEN), 202f Keloids, 206–207, 208f metastatic carcinoma, 479 Keratoacanthoma, 196, 197f Infundibular cyst, 188f Keratosis pilaris, 71, 73f Injecting drug use, cutaneous signs of, 570, Klippel-Trénaunay-Weber syndrome, 176, 571f 179 Insect bites and infestations, 820–857 Koebner phenomenon, 314, 317f arthropod bites, cutaneous reactions to, Koenen’s tumors, 437 820–825, 822f–825f Kraurosis (lichen sclerosus), 128–130, 129f cutaneous larva migrans (CLM), 844–846, KS. See Kaposi’s sarcoma 845f, 845t, 847f leishmaniasis. See Leishmaniasis L pediculosis, 826–833 Lamellar ichthyosis, 76–77, 77f pediculosis capitis, 827–830, 829f Langerhans cell histiocytosis (LCH), pediculosis corporis, 833, 833f 508–512, 509f, 509t–510t, 511f, 513f pediculosis pubis (phthiriasis), 830–832, Late-onset prurigo of pregnancy, 406–408, 831f–832f 407f–408f scabies. See Scabies LC (leukemia cutis), 518–520, 519f, 521f water-associated, 848–850, 848t, 849f–850f LE. See Lupus erythematosus Interferon-α-induced necrosis, 549, 551f Leg ulcers, 468–473, 469f, 471f, 473f Intertrigo, 584, 584f–585f, 710, 710f–713f arterial, 468, 471f, 472–473

1032 INDEX 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1033

hypertension, associated with, 470, 471f Lichenoid drug eruptions, 547 neuropathic and diabetic, 468, 470, Lighting techniques, 1015 472–473 Lime dermatitis, 221, 222f venous, 468–469, 469f, 472–473 Linear IgA dermatosis, 105, 105f Leiner’s disease, 47 Lipodystrophy syndrome, HIV-associated, Leishmaniasis, 851–856, 853f, 855f, 857f 921–923, 922f–923f classification, 851 Lipoma, 203f management, 856 Lipomatosis, 203f mucous membrane, 854 Livedo reticularis, 358–360 New World, 854, 857f Sneddon’s syndrome, 358, 359t, 360 Old World, 852, 853f, 854, 855f symptomatic (livedo racemosa), 358–360, Leishmaniasis recidivans, 854 359f, 359t Lentiginoses, genital, 988, 989f LM (lentigo maligna), 291–292 Lentigo maligna (LM), 291–292 LMM (lentigo maligna melanoma), 291–292, Lentigo maligna melanoma (LMM), 291–292, 292f, 308f 292f, 308f LP. See Lichen planus Leonine facies, 535, 541f LS. See Lichen sclerosus Lepidoptera, 823 LSC. See Lichen simplex chronicus Leprosy, 654–660, 657f, 658t, 659f–660f Lucio’s reaction, 656, 660 borderline, 654–656, 658, 660f Lues. See Syphilis epidemiology, 654 Lupus erythematosus (LE), 361–372, 982, 982f lepromatous, 654–656, 658–659, 659f diagnosis, 364, 366t pathogenesis, 655–656 Gilliam’s classification, 362t tuberculoid, 654–655, 657f, 658 systemic lupus erythematosus (SLE), Letterer-Siwe syndrome, 508–512, 509f, 361–367 509t–510t, 511f, 513f acute (ACSLE), 361–362, 362t, 363f, Leukemia cutis (LC), 518–520, 519f, 521f 364, 366t, 367, 367f Leukoderma, anogenital, 990 chronic (CCLE), 361, 362t, 365f, Leukoplakia, 983 369–371, 371f–372f LGV (), 907–909, subacute (SCLE), 361, 362t, 364f, 909f 368–369 Lice. See Pediculosis Lupus erythematosus-like syndrome (drug re- Lichen aureus, 131, 133 action), 548 Lichen planus (LP), 114–118, 115f, 116t, Lupus erythematosus profundus, 370–371, 117f, 119f, 981, 981f 372f actinicus, 114 Lupus panniculitis, chronic, 370–371, 372f anogenital, 993, 993f–994f Lupus pernio, 403, 405f disorders with similar eruptions, 116, 116t Lyell’s syndrome. See Toxic epidermal necrol- drug-induced, 116t ysis follicular, 114 Lyme borreliosis, 124, 672–683, 675f–679f, hypertrophic, 114, 116, 117f 681f mucous membrane, 114, 116 acrodermatitis chronica atrophicans, 674, nails, 954, 957f 676, 678f–679f, 680, 681f reticular, 114, 119f borrelial lymphocytoma, 673, 677f ulcerative, 114 deer tick feeding, 675f vesicular, 114 epidemiology, 672 Lichen purpuricus. See Lichen aureus erythema migrans, 673–674, 675f–676f, Lichen sclerosus (LS), 128–130, 129f 676, 680 anogenital, 998, 999f management, 680–681 genital, 128 secondary lesions, 673–674, 677f nongenital, 128 staging, 673 Lichen sclerosus et atrophicus. See Lichen Lymphadenitis, nonbacterial regional (cat- sclerosus scratch disease), 643–644, 645f Lichen simplex chronicus (LSC), 36–38, Lymphangitis, 604, 618, 619f 37f–38f, 996, 996f Lymphatic malformation (lymphangioma), 187f distribution, 36, 37f Lymphogranuloma inguinale, 907–909, 909f

INDEX 1033 3038r_ind_1023-1041 4/17/01 3:03 PM Page 1034

Lymphogranuloma venereum (LGV), anogenital, 1006, 1006f–1007f 907–909, 909f classification, 272 Lymphomas and sarcoma, 522–545 desmoplastic, 293–294, 294f adult T cell leukemia/lymphoma (ATLL), epidemiology, 270 532–533, 533f–534f follow-up, 307t cutaneous B cell lymphoma, 543, 543f–544f in situ, 277f, 282–284, 283f cutaneous T cell lymphoma (CTCL), screening technique for melanoma risk, 535–537, 537f–541f 282 classification, 536t–537t lentigo maligna (LM), 283f, 291–292 management, 536–537 lentigo maligna melanoma (LMM), Sézary’s syndrome, 535, 537, 542 291–292, 292f, 307f dermatofibrosarcoma protuberans, 545, 545f localization, 311f Kaposi’s sarcoma. See Kaposi’s sarcoma management, 302 lymphomatoid papulosis, 522–524, 523f metastatic, 299, 300f–301f Lymphomatoid papulosis, 522–524, 523f mucosa, malignant, 298 Lymphoreticulosis, benign (cat-scratch dis- nails, 956, 957f ease), 643–644, 645f nodular melanoma (NM), 289–290, 290f, 310f M oral, 985, 985f Macroglossia, 336, 337f overview, 270–272, 271t Macule, 1008f precursors, 270–281 Maculopapular drug reaction (exanthematous Clark melanocytic nevus (CMN), drug reactions), 547, 552–555, 553f 272–276, 274t, 275f, 277f Madura foot, 726–728, 727f, 728t classification, 272 Maduromycetoma, 726–728, 727f, 728t congenital nevomelanocytic nevus Magnification techniques, 1015 (CNN), 278–280, 279f, 281f Majocchi’s disease, 131, 133f recurrent, 483f Male-pattern baldness, 932–936, 933f, signs of, 302 935f–936f staging and work-up, 306t–307t Malignant appendage tumors, 268 superficial spreading melanoma (SSM), 277f, Mammary Paget’s disease (MPD), 484, 485f 283f, 284–286, 285f, 287f–288f, 309f Marfucci’s syndrome, 179 Melasma, 327–328, 329f Mark (capillary hemangioma of infancy), Meleney’s gangrene, 616 173–174, 174f–175f Meningococcemia, 637–638, 639f, 640, 641f Martorell’s ulcer, 470, 471f Merkel cell carcinoma, 269 Mastocytosis, 514–516, 514t, 515f, 516t, 517f Metabolic diseases. See Genetic, metabolic, Measles, 770–771, 771f–772f, 773–774, 775f endocrine, and nutritional diseases MED (minimum erythema dose), 211 Metastatic cancer to the skin, 479–483, Melanocytes, disorders of, 160–172 480f–481f, 483f acquired melanocytic nevocellular nevi, patterns of cutaneous involvement, 160–161 479–480, 482 blue nevus, 166, 167f Mibelli, angiokeratoma of, 183f compound melanocytic nevocellular nevi, Microscopic examinations, 1016 161, 163f Midges, 822 dermal melanocytic nevocellular nevi, 162, Migratory glossitis, 975, 975f 163f Migratory necrolytic erythema, 490, 491f halo nevomelanocytic nevus, 164, 165f Migratory phlebitis, 460 junctional melanocytic nevocellular nevi, Mikulicz, recurrent aphthae of, 976 161, 162f Milium, 190f Mongolian spot, 171f Milker’s nodules, 758, 759f nevus of Ota, 172f Minimum erythema dose (MED), 211 nevus spilus, 170f Minocycline-induced pigmentation, 566, 569f spitz nevus, 168–169, 169f Mites, 820–821 Melanoma, 270–311 Mohs surgery, 262, 262f acral lentiginous melanoma (ALM), Molluscum contagiosum, 754–757, 756f–757f 295–296, 297f in HIV disease, 925

1034 INDEX 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1035

Molluscum syncosis, 595 , 961–967, 963f, 965f Mondor’s disease, 460 normal nail apparatus, 953f Mongolian spot, 171f Necrobiosis lipoidica, 415–416, 416f Moniliasis. See Candidiasis Necrotizing fasciitis, 614, 616 Morbilli, 773–774, 775f Necrotizing soft tissue infection, 604 Morbilliform drug reaction (exanthematous Necrotizing vasculitis, 381–384, 382f–383f drug reactions), 547, 552–555, 553f Neisseria gonorrhoeae infections, 882–887, Morphea, 123–124, 125f–127f, 128, 130 883f, 886f, 888f circumscribed, 123, 125f disseminated, 887, 888f frontoparietal, 123 localized (gonorrhea), 885–886, 886f generalized, 123, 126f management, 883–885 linear, 123, 127f Neoplasms, benign. See Benign neoplasms pansclerotic, 123 and hyperplasias Moths, 821 Neurofibromatosis (NF), 440–442, 441f, 443f MPD (mammary Paget’s disease), 484, central or acoustic (NF2), 440, 442 485f von Recklinghausen’s (NF1), 440, 441f, Mucha-Habermann disease, 134, 135f 442, 443f Mucocele, 978, 978f Neuropathy, diabetic, 413, 413f Mucocutaneous lymph node syndrome Neurotic excoriations, 573f–575f (Kawasaki’s disease), 397–399, Nevus(i) 398f–399f araneus, 182f Mucosa Becker’s, 198f buccal and gingival, 976–979, 977f–978f blue, 166, 167f malignant melanoma of, 298 blue rubber bleb, 179 mucosal candidiasis in HIV disease, 924 capillary hemangioma of infancy, 173–174, viral infections of. See Viral infections of 174f–175f skin and mucosa Clark melanocytic, 272–276, 274t, 275f, Mucous cyst, 191f 277f Multiple idiopathic hemorrhagic sarcoma. See dysplastic melanocytic, 272–276, 274t, Kaposi’s sarcoma 275f, 277f Munchausen’s syndrome, 578, 578f epidermal, 202f Mycetoma, 726–728, 727f, 728t epithelioid spindle-cell, 168–169, 169f Mycobacterial infections, 654–671 flammeus, 173, 176, 177f–178f cutaneous nontuberculous infections, giant congenital nevocellular, 276, 278, 666–671 280, 281f M. foruitum complex, 670–671, 671f halo nevomelanocytic, 164, 165f M. marinum, 666–668, 667f nevocellular M. ulcerans, 668–669, 669f acquired, 160–161 cutaneous tuberculosis infections, 661–666, compound, 161, 163f 663f–665f dermal, 162, 163f epidemiology, 654 junctional, 161, 162f leprosy. See Leprosy nevomelanocytic, 164, 165f Mycosis fungoides. See Cutaneous T cell lym- organoid, 201f phoma of Ota, 172f Mycotic stomatitis, 714–716, 715f, 717f pigmented spindle-cell, 168–169, 169f Myleran-induced pigmentation, 568 sebaceous, 201f Myrmecia, 760–762, 761t, 762f–763f, 765f small congenital nevus cell nevi, 280 Myxedema, 422, 423f spilus, 170f Myxoid pseudocyst, 191f spitz, 168–169, 169f strawberry, 173 N NF. See Neurofibromatosis Nail disorders, 952–973 Nikolsky phenomenon, 94, 1016 as clues to multisystem diseases, 968–969, Nitrofurantoin drug reaction, 554 969f–973f Nodular melanoma (NM), 289–290, 290f, cutaneous, 954–956, 955f–957f 310f infections, 958, 959f–960f Nodular metastatic carcinoma, 481f, 482

INDEX 1035 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1036

Nodular vasculitis, 395, 396f mammary, 484, 485f Nodule, 1010f Palmoplantar pustulosis, 66, 67f Nonbiting flies, 821 Panarteritis nodosa, 384–386, 385f Nonclostridial anaerobic cellulitis, 616 Panniculitis, 146, 147f, 147t Nonsteroidal anti-inflammatory drugs α1 antitrypsin-deficiency, 146 (NSAIDs), reactions to, 552, 556 idiopathic lobular (Pfeiffer-Weber-Christian North American blastomycosis, 740–742, 741f disease), 146 NSAIDs (nonsteroidal anti-inflammatory lobular, 146, 147t drugs), reactions to, 552, 556 pancreatic, 146, 147f Nummular eczema, 42, 43f septal, 146, 147t Nutritional diseases. See Genetic, metabolic, Papule, 1009f endocrine, and nutritional diseases Paraneoplastic pemphigus (PNP), 96, 495, 495f O Parapsoriasis en plaques, 109–110, 110f–111f Oculocutaneous albinism, 322, 323t, 324, cutaneous T cell lymphoma (CTCL), pro- 325f gression to, 109–110 Ohio Valley disease, 737–738, 739f large plaque, 109, 111f , 954, 955f small plaque (digitate dermatosis), 109, Onycholysis, 954, 955f 110f Onychomycosis, 961–967, 963f, 965f Parasitosis, delusions of, 576, 576f–577f Oral hairy leukoplakia (OHL), 919–920, 920f , 958, 959f Orf, human, 758, 759f Pastia’s lines, 626, 627f Organoid nevus, 201f Patch testing, 1016 Oriental sore. See Leishmaniasis Pediculosis, 826–833 Oropharynx disorders, 974–987 Pediculosis captis, 827–830, 829f buccal and gingival mucosa, 976–979 Pediculosis corporis, 833, 833f apthous ulcer, 976–977, 977f Pediculosis pubis (phthiriasis), 830–832, mucocele, 978, 978f 831f–832f oral fibroma, 979, 979f Pellagra, 433, 433f bullous diseases with oral manifestations, Pemphigoid, 980 980–982, 980f–982f bullous, 98–100, 99f–100f lichen planus, 981, 981f cicatricial, 101, 101f lupus erythematosus, 982, 982f Pemphigus pemphigoid, 980 familial benign, 92, 93f pemphigus vulgaris, 980, 980f paraneoplastic (PNP), 96, 495, 495f precancerous and cancerous lesions, Pemphigus erythematosus (PE), 96 983–986, 983f–987f Pemphigus foliaceus, 96 condyloma acuminatum, 986, 986f–987f Pemphigus vegetans, 96 invasive squamous cell carcinoma, 984, Pemphigus vulgaris, 94–97, 95f, 97f, 980, 984f 980f leukoplakia, 983 Penicillin-induced urticaria, 559f oral melanoma, 985, 985f Penile intraepithelial neoplasm, 869 squamous cell carcinoma in situ (erythro- Penile lentigo, 988, 989f plasia), 983, 983f Periadenitis mucosa necrotica recurrens, 976 tongue, 974–975, 974f–975f Periarteritis nodosa, 384–386, 385f fissured tongue, 975, 975f Perifolliculitis, dissecting, 941, 944f hairy tongue, 974, 974f Perineum. See Genitalia, perineum, and anus, migratory glossitis, 975, 975f disorders of Osler-Weber-Rendu syndrome, 419, 419f Periocular xanthoma, 445, 446f Osler’s nodes, 632, 633f , 12, 13f Ota, nevus of, 172f Periorbital dermatitis, 13f , 8 Peutz-Jeghers syndrome (PJS), 492, 492f Pfeiffer-Weber-Christian disease, 146 P Phenolphthalein-induced drug reactions, 561f Paget’s disease, 482, 484–487, 485f, 487f Phenothiazine-induced drug reaction, 554, 568 extramammary, 486–487, 487f Phenytoin-induced drug reactions, 565f, 567

1036 INDEX 3038r_ind_1023-1041 4/11/01 2:14 PM Page 1037

Photoaging. See Dermatoheliosis Polymorphic eruption of pregnancy, 406–408, Photopatch testing, 1016 407f–408f Photosensitivity and photoinduced disorders, Polymorphous light eruption, 230–232, 231f, 210–247 233f classification and overview, 210 Porphyrias, 238–247 diagnosis, 234, 235t, 236, 237t erythropoietic, 245–247, 246f–247f drug-induced photosensitivity, 223–229, 547 porphyria cutanea tarda, 238–240, 238t, photoallergic drug-induced, 227–228, 240f–241f, 241t 228f–229f drug reaction, 547 phototoxic drug-induced, 223–225, variegate, 242–244, 243f, 244t 224f–225f, 226t Port-wine stain, 176, 177f–178f management, 236 Postinflammatory hyperpigmentation, 330, Phototypes, skin, 212t 330f Phthisis, 661 Postinflammatory hypomelanosis, 331, Phytophotodermatitis, 221, 222f 331f–332f Pigmentary disorders, 312–333 Poxvirus infections, 754–759 albinism. See Albinism human orf, 758, 759f drug reactions, 549, 566–568, 567f, 569f Milker’s nodules, 758, 759f specific drugs, 566–568 molluscum contagiosum, 754–757, following of the skin, 756f–757f 330–331, 330f–333f Precancerous lesions and cutaneous carcino- melasma, 327–328, 329f mas, 248–269 vitiligo. See Vitiligo epidermal, 248–254 Pigmented lesions, management (to facilitate invasive squamous cell carcinoma, 257–260 early diagnosis of melanoma), 302 malignant appendage tumors, 268 Pigmented purpuric dermatoses, 131–133, radiation dermatitis, 252–254 132f–133f Pregnancy, diseases in, 406–410 Gougerot-Blum disease, 131, 133 herpes gestationis, 409–410, 410f lichen aureus, 131, 133 pruritic urticarial papules and plaques, Majocchi’s disease, 131, 133f 406–408, 407f–408f Schamberg’s disease, 131, 132f Pressure sore, 474–477, 475f–476f Pigmented spindel-cell nevus, 168–169, 169f Pressure ulcers, 474–477, 475f–476f Pilar cyst, 189f stages, 474 Pinch purpura, 335f Progesterone-induced pigmentation, 568 Pitted keratolysis, 582–583, 583f Progressive bacterial synergistic gangrene, Pityriasis alba, 331, 333f 616 Pityriasis lichenoides, 134, 135f Progressive systemic sclerosis. See Sclero- Pityriasis lichenoides chronica, 134, 135f derma Pityriasis lichenoides et varioliformis acuta Prosthetic valve endocarditis, 631 (Mucha-Habermann disease), 134, 135f Pruritic urticarial papules and plaques, Pityriasis rosea, 106–108, 107f 406–408, 407f–408f distribution, 107f Pruritus, generalized, without diagnostic skin drug reactions, 548 lesions, 425, 425t–427t, 427f herald patch, 107f Pruritus ani, 427, 427f, 996, 997f Pityriasis sicca (dandruff), 45–48, 47f Pseudofolliculitis barbae, 941, 945f Pityriasis versicolor, 331, 331f, 722–724, Pseudolymphoma drug reaction, 548 723f, 725f Pseudomonas aeruginosa infections, 652–653 Pityrosporum folliculitis, 594, 599f , 941, 942f–943f PJS (Peutz-Jeghers syndrome), 492, 492f Pseudoxanthoma elasticum (PXE), 434–436, Plantar warts, 761–762, 765f 435f–436f Plaque, 1009f Psoriasis, 50–69, 52f–55f, 57f, 58t, 59f, 61f, Plumber’s itch. See Cutaneous larva migrans 62t, 63f–65f PNP (paraneoplastic pemphigus), 96, 495, 495f anogenital, 991, 991f–992f Poison ivy dermatitis, 26–28, 28f–29f arthritis, 51–52, 64f Poison oak dermatitis, 26–28 body folds, 65 Polyarteritis nodosa, 384–386, 385f distribution, 52f, 55f

INDEX 1037 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1038

drug reaction, 548 Rheumatic diseases, skin signs of. See Im- erythroderma, 51 mune, autoimmune, and rheumatic dis- generalized acute pustular psoriasis (von eases, skin signs of Zumbusch), 68–69, 69f , 8, 10, 11f nails, 64, 64f, 954, 956f Rickettsial infections, 746–753, 766 palmoplantar pustulosis, 66, 67f Rocky Mountain spotted fever, 750–752, palms and soles, 63, 63f–64f 752f–753f perianal and genital regions, 65, 65f spotted fevers, 746–753 scalp, 56, 57f etiology and geographic distribution, 747 widespread, 58, 58t, 59f, 60–62, 61f, , 748, 749f 62t tâche noire, 749f management, 58–62, 58t, 62t Rickettsialpox, 748, 749f Psychiatric etiology, disorders of, 572–579 Ringworm, 688 delusions of parasitosis, 576, 576f–577f beard, 706, 706f–707f dysmorphic syndrome, 579 scalp, 700–704, 701f–702f, 705f Munchausen’s syndrome, 578, 578f Rocky Mountain spotted fever, 750–752, neurotic excoriations, 573f–575f 752f–753f Pubic lice, 830–832, 831f–832f Rosacea, 8–10, 9f, 11f Purpura drug reaction, 547–548 blepharophyma, 8 Purpura fulminans, 500, 501f, 503f gnathophyma, 8 Pustular drug eruptions, 548 otophyma, 8 Pustular psoriasis, acute (von Zumbusch), rhinophyma, 8, 10, 11f 68–69, 69f Rosacea-like dermatitis, 12, 13f Pustule, 1011f Roseola infantum, 818, 819f Pustulosis, palmoplantar, 66, 67f RS (Reiter’s syndrome), 400–402, 401f PXE (pseudoxanthoma elasticum), 434–436, Rubella, 770–771, 771f–772f 435f–436f Rubeola, 773–774, 775f Pyodermas, 586–603 abscess, furuncle, and carbuncle, 600–602, S 601f, 603f Sailor’s skin, 214 impetigo and ecthyma, 586–590, 587f–589f, Salmon patch, 176 591f Sand fleas, 821 infectious folliculitis. See Infectious folli- Sandworm eruption. See Cutaneous larva mi- culitis grans pathogenesis, 586 San Joaquin Valley fever, 743–744, 745f gangrenosum, 148, 149f Sarcoidosis, 403–404, 404f–405f Pyogenic granuloma, 184, 185f Sarcoma. See Lymphomas and sarcoma Scabies, 834–842, 837f, 839f, 841f, 843f Q crusted or Norwegian scabies, 838, 840, Queyrat, erythroplasia of, 260f 841f, 842 Quinacrine-induced pigmentation, 567 distribution, 837f, 838 elderly, 838 R epidemiology, 834 Rabbit fever, 649–650, 651f infants and young children, 838, 839f Radiation dermatitis, 252–254, 253f–254f laboratory diagnosis, 1016–1017 squamous cell carcinoma in situ, 255–256, nodular scabies, 838, 839f, 840, 842 256f Scaling (desquamation), 1013f Ranula, 978, 978f Scarlet fever, 626–628, 627f, 629f Rashes in acutely ill febrile patients, 158–159, Scars, hypertrophic, 206–207, 207f 159t SCC. See Squamous cell carcinoma diagnosis, 158–159, 159t Schamberg’s disease, 131, 132f Raynaud’s disease/phenomenon, 373, 375f, Schistosome dermatitis, 848t, 849, 849f 377–380, 377f, 379f–380f Schönlein-Henoch purpura, 384 acrogangrene, 378, 380f Scleroderma, 373–377, 375f–377f causes, 379t circumscribed, 123–124, 125f–127f Reiter’s syndrome (RS), 400–402, 401f Crest syndrome, 374, 377, 377f

1038 INDEX 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1039

drug reaction, 548 Skin lesion, types, 1008–1014 localized, 123–124, 125f–127f bulla, 1011–1012 scleroderma-like conditions, 377 crusts, 1013f Sclerosing hemangioma, 204, 205f desquamation (scaling), 1013f SCNN (small congenital nevus cell nevi), 280 macule, 1008f Scorpions, 821 nodule, 1010f Scrotal tongue, 975, 975f papule, 1009f Scrum pox. See Herpes simplex virus plaque, 1009f Scurvy, 428–429, 429f pustule, 1011f Seabather’s eruption, 848t, 850, 850f ulcer, 1014f , 188f vesicle, 1011f–1012f Sebaceous glands, 2–13 wheal, 1010f Sebaceous hyperplasia, 200f Skin phototypes, 212t Sebopsoriasis, 47f Skin tag, 209f Seborrheic dermatitis, 45–48, 46f–47f Small congenital nevus cell nevi (SCNN), 280 distribution, 45–46 Sneddon’s syndrome, 359t, 360 Seborrheic keratosis, 192–193, 193f–195f Soft , 901–904 Sedge pool itch, 848t, 849, 849f Soft fibroma, 209f Senear-Usher syndrome, 96 Soft tissue infections, bacterial. See Bacterial Senile (hem)angioma, 181f infections, soft tissue infections Senile sebaceous hyperplasia, 200f Solar keratosis, 217, 219, 220f Sepsis and septic shock, 636–640, 639f, 641f Solar lentigines, 219f epidemiology, 636 Solar lentigo, 217, 218f management, 640 Solitary histiocytoma, 204, 205f physical examination, 637–638 Spider angioma, 182f Serum sickness, 547 Spider nevus, 182f Sexually transmitted diseases (STDs), 858–909 Spider telangiectasia, 182f chancroid, 901–904, 902f–903f Spiders, 821 donovanosis, 905–906, 906f Spitz nevus, 168–169, 169f genital herpes. See Genital herpes Sporotrichosis, 731–732, 733f human papillomavirus (HPV) mucosal in- Spotted fevers, 746–753 fections, 862–873, 863f–867f Squamous cell carcinoma (SCC) management, 866–868 in situ, 255–256, 256f, 983, 983f squamous cell carcinoma of anogenital anogenital, 1000–1002, 1000f–1001f, skin, 869–872, 870f–873f 1003f lymphogranuloma venereum (LGV), nails, 954, 957f 907–909, 909f invasive, 257–260 management, 858 Staphylococcal scalded–skin syndrome Neisseria gonorrhoeae infections, 882–887, (SSSS), 620–622, 621f, 623f 883f, 886f, 888f Statis dermatitis, 462, 464, 465f, 469 disseminated, 887, 888f STDs. See Sexually transmitted diseases localized (gonorrhea), 885–886, 886f Stevens-Johnson syndrome, 140–143, 141f, management, 883–885 547 overview, 858, 859t–861t Strawberry nevus, 173 syphilis. See Syphilis Sturge-Weber syndrome, 176 Sézary’s syndrome, 535, 537, 542 Sulfonamides, drug reaction to, 554 Shingles (herpes zoster), 805–808, 807f, 809f Sun damage, acute (sunburn), 211–213, 213f Silver-induced pigmentation, 568 skin phototypes, 211, 212t Sister Mary Joseph nodule, 482 Superficial spreading melanoma, 277f, 283f, Sjögren syndrome, 403 284–286, 285f, 287f–288f, 309f Skin and hair, fungal infections Sutton’s disease, 976 candidiasis. See Candidiasis Sutton’s leukoderma acquisitum centrifugum, dermatophytoses. See Dermatophytoses 164, 165f invasive infections. See Invasive fungal in- Sweet’s syndrome, 150, 151f fections Swimmer’s itch, 848t, 849, 849f pityriasis versicolor, 722–724, 723f, 725f Swimming pool granuloma, 666–668, 667f

INDEX 1039 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1040

Symptomatic primary HIV infection, Transient acantholytic dermatosis, 112, 113f 912–915, 915f, 915t Traumatic epidermoid cyst, 190f Synergistic necrotizing cellulitis, 616 Traumatic fibroma, 979 Synovial cyst, 191f Trichilemmal cyst, 189f Syphilis, 889–904 Trichoepithelioma, 199f classification of clinical stages, 890 Tricholemmomas, 488, 489f in HIV disease, 900 Tuberculosis, cutaneous, 661–666, 663f–665f laboratory examinations, 889–891 acute miliary (AMT), 661–662, 666 latent, 899 (LV), 661–662, 664, 664f, 666 management, 891–892 metastatic abscess (MTA), 661–662, 664, primary, 890, 892, 893f–894f 666 secondary, 890, 895, 896f–898f orificial (OT), 661–662, 664, 665f tertiary, 890, 899, 900f primary inoculation tuberculosis, 661–662, variation in HIV disease, 925 663f, 666 Syphilitic folliculitis, 595 , 661–662, 664, 665f, 666 Syringoma, 199f Tuberculosis verrucosa cutis, 661–662, 663f, Systemic lupus erythematosus. See entry 664, 666 under Lupus erythematosus Tuberous sclerosis, 437–438, 438f–439f Systemic scleroderma. See Scleroderma Tuberous xanthoma, 448, 448f Systemic sclerosis. See Scleroderma Tularemia, 649–650, 651f Tumors T glomus, 186f Tabandae, 822 Koenen’s, 437 Telangiectasia, hereditary hemorrhagic, 419, malignant appendage, 289 419f Tungiasis, 823, 825, 825f Telangiectatic carcinoma, 479, 481f Telogen effluvium, 937–939, 938t–939t, 939f U Temporal arteritis, 390–391, 391f–392f Ulcers, 1014f TEN (toxic epidermal necrolysis), 140–143, aphthous, 976–977, 977f 141f, 547 Bairnsdale, 668–669, 669f Tendinous xanthoma, 447, 447f Buruli, 668–669, 669f Tetracycline-induced drug eruption, 563f decubitus, 474–477, 475f–476f Thrombocytopenic purpura, 496–498, 497f, leg. See Leg ulcers 499f Martorell’s, 470, 471f Thrombophlebitis, 458–460, 459f pressure, 474–477, 475f–476f Thrush, 714–716, 715f, 717f Ulcus molle, 901–904 Ticks, 821 Urticaria. See Angioedema and urticaria Tinea barbae, 706, 706f–707f Tinea capitis, 594, 700–704, 701f–702f, 705f V Tinea corporis, 696–697, 696f–697f Vaccines, drug reaction to, 556 Tinea cruris, 694, 695f Valley fever, 743–744, 745f Tinea facialis, 698–699, 698f–699f, 707f Varicella-zoster virus (VZV) infections, 800–819 Tinea incognito, 699, 699f epidemiology, 800 Tinea manuum, 693–694, 693f herpes zoster (HZ), 805–808, 807f, 809f Tinea pedis, 688–690, 689f, 691f–692f in HIV disease, 925 Tinea tonsurans, 700–704, 701f–702f, 705f immunocompromised host, 812–816, 813f, Tinea versicolor. See Pityriasis versicolor 815f, 817f Tongue disorders, 974–975, 974f–975f laboratory examinations, 801–802 Torulosis, 734–736, 735f pathogenesis, 800 Toxemic rash of pregnancy, 406–408, varicella, 801–804, 803f 407f–408f Varicose veins, 462, 463f, 467 Toxic epidermal necrolysis (TEN), 140–143, Variegate porphyria, 242–244, 243f, 244t 141f, 547 Vascular hamartomas, 179 Toxic oil syndrome, 377 Vascular insufficiency, skin signs of, 452–477 Toxic shock syndrome, 624–626, 625f atherosclerosis, atheroembolization, and ar- Toxicodendron dermatitis, 26–28, 28f–29f terial insufficiency, 452–457

1040 INDEX 3038r_ind_1023-1041 4/13/01 11:32 AM Page 1041

chronic venous insufficiency, 462–467 differential diagnosis, 315–316 leg ulcers, 468–473 distribution, 314–315, 314f pressure ulcers, 474–477 repigmentation, 317f, 318–320, 321f thrombophlebitis and deep venous thrombo- Vitiligo universalis, 315, 319f sis, 458–461 Vulvar intraepithelial neoplasia, 869 Vascular spider, 182f Vulvar melanosis, 988, 989f Vasculitis, 381–396 Vulvitis, 718, 719f giant cell arteritis, 390–391, 391f–392f hypersensitivity vasculitis, 381–384, W 382f–383f Waldenström’s macroglobulinemia, 504 nodular, 395, 396f Warfarin-induced necrosis, 549, 549f polyarteritis nodosa, 384–386, 385f Warts Schönlein-Henoch purpura, 384 epidermodysplasia verruciformis, 762 urticarial vasculitis, 393–394, 394f management, 764 Wegener’s granulomatosis (WG), 386–389, verruca plana (flat warts), 761–762, 765f 387f–389f verruca plantaris (plantar warts), 761–762, Venereal warts. See Human papillomavirus, 765f sexually transmitted verruca vulgaris (common warts), 761–762, Venous lake, 180f 762f–763f Verruca, 760–762, 761t, 762f–763f, 765f Water-associated infections and infestations, Vesicle, 1011f–1012f 848–850, 848t, 849f–850f Viral infections of skin and mucosa, 754–819 Wegener’s granulomatosis (WG), 386–389, herpesviruses. See Human herpesviruses 387f–389f (HHV) Wen, 188f human papillomavirus infections. See Hu- Wheal, 1010f man papillomavirus infections Wickham’s striae, 114, 115f, 119f, 981, infectious exanthems, 766–780 981f erythema infectiosum, 778–780, Wood’s lamp, 1015 779f–780f hand-foot-and-mouth disease (HFMD), X 776–778, 777f X-linked ichthyosis (XLI), 74–75, 75f measles, 773–774, 775f Xanthelasma, 445, 446f overview, 766–767, 767f–769f Xanthelasma palpebrarum, 445, 446f rubella, 770–771, 771f–772f Xanthoma striatum palmare, 450, 450f poxvirus infections, 754–759 Xanthoma tendineum, 447, 447f human orf, 758, 759f Xanthoma tuberosum, 448, 448f milker’s nodules, 758, 759f Xanthomas, 444–450, 444t, 446f–450f molluscum contagiosum, 754–757, eruptive, 449, 449f 756f–757f varicella-zoster virus (VZV). See Varicella- Z zoster virus infections Zidovudine-induced pigmentation, 566 Vitamin C deficiency, 428–429, 429f Zinc deficiency, 430–431, 431f Vitiligo, 312–320, 313t, 314f–315f, 317f, 319f, Zoster sine zoster, 805 321f anogenital, 990, 990f

INDEX 1041 3038r_last_ibc 4/7/01 9:50 AM Page 1042

Recognize these skin alterations during the routine physical examination (Numbers in parentheses refer to pages where disorder is discussed.) Psoriasis (50) Seborrheic dermatitis (45) Xanthelasma (445) Solar lentigo (217) Melasma (327) Actinic keratosis (217) Solar keratosis (in exposed areas) (217) Basal cell carcinoma (261) Rosacea (8) Squamous cell carcinoma (257) Acne (2) Perioral dermatitis (12) Seborrheic keratosis (192) Seborrheic dermatitis (45) Venous lake (180) Acrochordon (skin tags) (209) Herpes labialis (781)

Spider angioma (182) Seborrheic dermatitis (45) Common acquired melanocytic nevus (160) Cherry angioma (181)

Dysplastic nevus (272) Atopic eczematous dermatitis (30)

Psoriasis (50)

Eczematous dermatitis (18) Verruca vulgaris (760)

Dermatofibroma (204) Candidiasis (708) Tinea cruris (694) Psoriasis (50) Psoriasis (50) Lichen simplex (36) Malignant melanoma (female) (311)

Ichthyosis (70)

Stasis dermatitis (462) Stasis ulcer (462) Fungal infection (Tinea pedis, interdigital) (688)

Fungal infections Racial pigmentation (onychomycosis) (961) (gums and buccal mucosa) Leukoplakia (983) Candidiasis (708) Lichen planus (114)

Migratory Fissured tongue (975) glossitis (975) 3038r_last_ibc 4/7/01 9:50 AM Page 1043

Recognize these skin alterations during the routine physical examination (Numbers in parentheses refer to pages where disorder is discussed.) Tinea capitis (700) Pilar cyst (189) Squamous cell carcinoma Actinic (solar) (bald males) (257) keratosis (tip of ear) (217) Psoriasis Seborrheic dermatitis (scalp and behind ears) (56) (scalp and behind ears) (45) Acne (2) Lichen simplex (36) Basal cell carcinoma (adult) (261) Dysplastic melanocytic nevus (272) Tinea versicolor (white or brown) (722) Melanoma (270) Seborrheic keratosis (192) Keratosis pilaris (71)

Psoriasis (50)

Café-au-lait macule (440) Congenital Actinic (solar) melanocytic nevi (278) keratosis (217) Melanoma (270) Solar lentigo (217) Fungal infection (958)

Scabies (834) Dyshidrotic eczema (39)

Folliculitis (595) Candidiasis (708) Dermatophyte infection (684) Pruritus ani (427) Atopic eczematous Lichen simplex (36) dermatitis (30) Psoriasis (50)

Melanoma (females) (311)

Verruca plantaris or clavus (760)

Tinea pedis (688)

HPV infections (760) Lichen simplex (36) CLITORIS Vitiligo (312) Psoriasis (50) URETHRAL MEATUS

giokeratoma (183) LABIUM HPV MAJUS infections LABIUM abetic nodules (838) (862) MINUS

Psoriasis (50) Secondary syphilis (890)